Evidence map›Paper›PMID 37633642›Full record

ArticleJournal of thrombosis and haemostasis : JTH2023

Cattle-FRETS71, a novel fluorogenic substrate with broad applicability for characterizing ADAMTS13 properties and function.

John Cameron Barton, Cooper Anderson, Frida Z Miranda, Rachel Kelley, Johanna A Kremer Hovinga, Deirdra Terrell, Sara K Vesely, James N George, Joshua Muia

Open access · bronzeAbstract read
In one paragraph

Article in Journal of thrombosis and haemostasis : JTH, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Arginine Methylation by PRMT1 Affects ADAMTS13 Secretion and Enzymatic Activity.Arteriosclerosis, thrombosis, and vascular biology · 2025
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

John Cameron BartonOklahoma State University College of Osteopathic Medicine, Tulsa, Oklahoma, USA.
Cooper AndersonOklahoma State University College of Osteopathic Medicine at the Cherokee Nation, Tahlequah, Oklahoma, USA.
Frida Z MirandaDepartment of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA.
Rachel KelleyDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Johanna A Kremer HovingaDepartment of Hematology and Central Hematological Laboratory, Bern University Hospital, University of Bern, Bern, Switzerland.
Deirdra TerrellDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Sara K VeselyDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
James N GeorgeDepartment of Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Joshua MuiaDepartment of Biochemistry and Microbiology, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA. Electronic address: jmuia@okstate.edu.
University of Oklahoma Health Sciences Center · USOklahoma State University Center for Health Sciences · USCherokee Nation · USOklahoma State University Medical Center · USUniversity of Bern · CH

Funding

Tissue Pathology Shared ResourceP30CA225520 · NCI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Resham Bhattacharya · 2018 to 2026
$27.1M
Training In Cardiovascular Physiology & PharmacologyT32HL007444 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Ju Chen, Robert Scott Ross · 1985 to 2026
$11.1M
UCSD PRIDE Faculty Development Program in Cardiovascular SciencesR25HL145817 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Robert Scott Ross, Joann Trejo · 2019 to 2026
$3.3M
Investigating the regulation and substrate processing of ADAMTS13 and ADAMTS7 metalloproteases.R35GM142926 · NIGMS · VERSITI WISCONSIN, INC. · PI MUIA, JOSHUA MUTAMBUKI · 2021 to 2025
$2.0M
Life after Recovery in Adult Thrombotic Thrombocytopenic Purpura (TTP): Let's Hear It from the SurvivorsK01HL135466 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TERRELL, DEIRDRA R · 2017 to 2021
$687k
NCI NIH HHS P30 CA225520NHLBI NIH HHS K01 HL135466NHLBI NIH HHS R25 HL145817NHLBI NIH HHS T32 HL007444NIGMS NIH HHS R35 GM142926
6 · The paper itself

Abstract

backgroundCurrent ADAMTS13 activity assays are important for diagnosing thrombotic thrombocytopenic purpura (TTP) but are unreliable to assay ADAMTS13 activity in animal models. The Cattle-FRETS71 assay is capable of detecting ADAMTS13 activity in plasma from multiple animal species, making it a potentially useful reagent at all stages of clinical research. The performance of Cattle-FRETS71 in TTP diagnosis is not yet known.

objectivesWe evaluated the performance of the Cattle-FRETS71 substrate against the human FRETS-rVWF71 and the FRETS-VWF73 commercial substrates in human plasma and serum samples to validate its utility in diagnosing TTP in patients.

methodsInternal validation was performed using heparinized plasma samples (n = 81). External validation was a blinded study using serum samples from the Oklahoma TTP Registry (n = 118, collected 2004-2014) that had been initially assayed by FRETS-VWF73 within 1 year of collection. Additional validation was performed with citrated plasma samples with variable ADAMTS13 activities (n = 32) that were analyzed by FRETS-VWF73.

resultsThere was an excellent correlation (r = 0.94) between Cattle-FRETS71 and FRETS-rVWF71 for assayed heparinized plasma samples (n = 81). Assay results between Cattle-FRETS71 and FRETS-VWF73 of Oklahoma TTP Registry serum samples (n = 118) and citrated plasma samples (n = 32) were comparably good (r = 0.81 and r = 0.85, respectively).

conclusionThe Cattle-FRETS71 assay is comparable with other assays in quantifying ADAMTS13 activity in human plasma collected from patients with documented or suspected TTP. The versatility of Cattle-FRETS71, combined with its specificity and sensitivity, makes it a useful tool for the standardization of ADAMTS13 activity across basic and clinical research paradigms.

Indexed as

Purpura, Thrombotic ThrombocytopenicADAM ProteinsADAMTS13 ProteinAnimalsCattleCitric AcidFluorescence Resonance Energy TransferFluorescent DyesHumansvon Willebrand FactorADAM ProteinsADAMTS13 ProteinADAMTS13 protein, humanCitric AcidFluorescent Dyesvon Willebrand FactorADAMTS13animal modelsenzyme assaysTTPvon Willebrand factor

Identifiers

PMID37633642
PMCPMC10840809
OpenAlexW4386170818

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.